Gerresheimer's Countdown to June: Impairments, Insider Buying, and a Missing Audit

Gerresheimer faces disconnect: stock surges 41% but drops 9% below 200-day MA as delayed annual report triggers BaFin, APAS, DSW probes, asset sales, and plant closure.

Gerresheimer finds itself in a peculiar spot. The stock has rallied roughly 41 percent over the past month, executives have snapped up nearly €10 million worth of shares, and the company is sticking to its 2026 revenue target of up to €2.4 billion. Yet the share price closed on Friday at €24.92, tumbled 9 percent on the week, and slipped below the 200-day moving average — a technical level closely watched by institutional investors.

The disconnect traces back to one unresolved document: the audited annual report. Delayed first from its original March deadline and now pushed to June, the testated financials have set off a chain reaction that postponed the annual general meeting, froze conventional financing triggers, and invited multiple regulatory probes.

A regulatory triple-header

Three separate oversight bodies are now combing through Gerresheimer's books. The German financial watchdog BaFin is scrutinising a set of interim accounts for potential misstatements related to leasing liabilities, capitalised development costs, and assets in the Advanced Technologies segment. Simultaneously, the audit oversight authority APAS is running a professional conduct investigation against KPMG, the former auditor that signed off on the 2024 accounts despite what are now acknowledged to be erroneous revenue bookings running into the millions. The German Shareholders' Association DSW has also stepped in, examining whether former executives bear responsibility for the discrepancies.

The board has already signalled that the 2025 accounts will take a heavy non-cash hit. Impairments of up to €240 million are expected, primarily linked to the Sensile Medical project and the Chicago glassworks that is slated to close by the end of 2026.

Buying time and selling assets

To ease the balance-sheet pressure, Gerresheimer is pressing ahead with the sale of its US consumer packaging subsidiary Centor. Morgan Stanley is managing the process, and more than ten potential suitors have expressed interest in the division, which carried a book value of roughly €300 million at the end of 2024. Management aims to close the deal before year-end.

Creditors have given the company some breathing room. Schuldschein holders agreed to extend the deadline for the audited financials to the end of September, and banks temporarily waived key covenant conditions. That buys Gerresheimer a window during which it must deliver the testated report — or risk a far more severe funding crunch.

A plant closure and a tech tie-up

On the operational front, the restructuring is gathering pace. The Chicago Heights plant, which employs around 170 people, will shut down in September 2026, with production moving to facilities in Italy and India. The move is part of a broader portfolio clean-out that also includes the Centor disposal.

Product innovation continues nonetheless. At the Interpack trade fair in Düsseldorf, Gerresheimer announced a partnership with US-based Milliken that boasts a 40 percent improvement in the moisture barrier of plastic packaging — a development that could strengthen its hand in the pharmaceutical packaging market.

All eyes on June

Despite the turmoil, the management is holding firm on its 2026 guidance for an adjusted EBITDA margin of between 18 and 19 percent. The first-quarter figures, originally due alongside the annual report, are also expected to land shortly after the June audit is completed.

The stock's relative strength index has sunk to around 28, a level many traders consider oversold. Annualised volatility stands at 69 percent, underscoring the extremes of recent weeks. Whether the share price rally of the past month is sustained — or fizzles as a technical bounce — now hinges entirely on what the testated annual report reveals when it finally arrives.